Condition (MeSH)
Diffuse Cerebral Sclerosis of Schilder
ClinicalTrials.gov lists 5 trials for Diffuse Cerebral Sclerosis of Schilder or a narrower condition beneath it. PTC Therapeutics has the most among industry and government lead sponsors, with 2.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
5 of the 5 trials are tagged with Diffuse Cerebral Sclerosis of Schilder itself; the rest are tagged with a narrower condition beneath it.
When did Diffuse Cerebral Sclerosis of Schilder trials start? (5)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 2
- Phase 2/3
- Phase 3
- Observational
Top of scale: 1
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2022 | 1 |
| 2020 | 1 |
| 2014 | 1 |
| 2009 | 1 |
| 1995 | 1 |
No forecast is made for this condition: it averages 0.2 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: none of the 5 trials evaluated at the 2026-10-09 snapshot is predicted and still running. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Diffuse Cerebral Sclerosis of Schilder trials in? (4)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 2 | 1 |
| Phase 2/3 | 1 |
| Phase 3 | 2 |
| Observational | 1 |
How many Diffuse Cerebral Sclerosis of Schilder trials are recruiting? (3)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Completed | 2 |
| Terminated | 2 |
| Unknown status | 1 |
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Diffuse Cerebral Sclerosis of Schilder trials? (3)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| PTC Therapeutics | 2 |
| National Institute of Neurological Disorders and Stroke (NINDS) | 1 |
| Novartis Pharmaceuticals | 1 |
Which serious adverse events do Diffuse Cerebral Sclerosis of Schilder trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Pneumonia | 20 | 2 |
| Seizure | 14 | 2 |
| Acute respiratory failure | 11 | 1 |
| COVID-19 | 10 | 2 |
| Vomiting | 10 | 2 |
Showing 5 of 10 adverse events.
Which publications cover Diffuse Cerebral Sclerosis of Schilder? (11)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Cerebral folate deficiency and CNS inflammatory markers in Alpers disease. | Molecular genetics and metabolism | 2010 | Yes |
| White matter lesions in patients with idiopathic normal pressure hydrocephalus and in an age-matched control group: a comparative study. | Neurosurgery | 1997 | Yes |
| Leukodystrophy in patients with ovarian dysgenesis. | Annals of neurology | 1997 | Yes |
| Clinical spectrum of CADASIL: a study of 7 families. Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy. | Lancet (London, England) | 1995 | Yes |
| The inherited leukodystrophies: a clinical overview. | Journal of inherited metabolic disease | 1993 | Yes |
Showing 5 of 11 publications.
Prevalence (2)
Shown in this order: jurisdiction, then disease name. Orphanet observation for the mapped ORPHA concept; the mapping relation column says whether that concept is exactly this condition or broader or narrower.
| Orphanet disease | Type | Class | Geography | Jurisdiction | Mapping relation |
|---|---|---|---|---|---|
| Schilder disease | Point prevalence | Unknown | Worldwide | Not stated | Exact |
| Schilder disease | Point prevalence | Unknown | Worldwide | Not stated | Exact |
Rare-disease identity (2)
Shown in this order: exact, broader, narrower, other.
| Orphanet disease | ORPHA code | Relation | Source |
|---|---|---|---|
| Schilder disease | 59298 | Exact | Orphadata Science knowledge files, Product 1 |
| Schilder disease | 59298 | Exact | Orphanet Rare Disease Ontology (ORDO) |
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: sub-conditions in mesh.
Not computed for conditions with fewer than 10 trials: drugs tested.